A report back on more than four years of HIV/AIDS disease management in Southern Africa by Regensberg, LD & Hislop, MS
AID FOR AIDS
L 0 Regensberg, lWB ChB, MRCP
M S Hislop, MSc
Aid/or AIDS Pry (Lcd), Private Bag XI003, Claremolll, 7735
A REPORT BACK ON MORE THAN FOUR
YEARS OF HIV/AIDS DISEASE MANAGEMENT
IN SOUTHERN AFRICA
The major challenge facing the acceptance of the
programme was the high cost of ART. Negotiations with
representatives from pharmacy groups resulted in ART
being made available at cost plus a dispensing fee of R50
per line item. Even so, the cost of the cheapest combination
was still very high, and concerns were raised as to the
viability of the programme and the ability of medical
schemes to sustain these costs on an on-going basis. Our
belief was that the drug costs would eventually come
down, and that highly active antiretroviral therapy [HAARn
would become the standard of care. Fortunately, this has
proved to be the case [Table I). However, only some
manufacturers have reduced ART prices substantially and
only a limited range of HAART can be made available.
CONSOUDATION AND GROWTH
The subsequent 4 years has seen a phenomenal growth in
AfA [Fig. 1), from a handful of contracted medical schemes
to 38, from dealing with South African medical schemes
only to providing the programme to multinational
companies throughout Africa, and from offering only a
disease management programme to offering a
comprehensive risk management solution for corporates.
Providers outside the country are able to register patients
by Internet and interact with clinical staff electronically.
around the country. The reasons for the scepticism were
twofold. Firstly, AfA was recommending ART only when the
CD4 count was less than 350!~1 or an AIDS-defining illness
was present. This was the era of 'hit early and hit hard', and
delaying therapy to the extent recommended was
considered close to heresy by the majority of experts.
Equally unacceptable to many was the use of dual therapy,
which was known to be inferior to triple therapy at the
time. However, dual therapy was all that was affordable for
most medical schemes and, although sub-optimal, had
clearly been shown to provide benefit for patients. Patients
were urged to buy the third drug themselves in order to
obtain the full benefit of ART, but few were able to afford
this.
------------ H9RUARY 2003
Aid for AIDS (AfA) was based on the premise that the major
cost driver in managing HIV!AIDS was hospitalisation for
AIDS-related conditions and that ART, although costly,
would be effective in terms of slowing progression of the
disease, reducing morbidity and improving survival' It was
felt that making ART available by way of a disease
management programme with careful monitoring, coupled
with education of patients and meaningful clinical support
of providers, would be cost-effective and benefit both the
funders of health care and, more importantly, those
beneficiaries who were living with HIV!AIDS.
The first Clinical Guidelines, now in a substantially revised
and expanded 4th edition, were presented to a somewhat
sceptical medical profession in a series of workshops
Prior to 1998 and the implementation of the Medical
Schemes Act, beneficiaries of medical aid schemes who
were living with HIV or AIDS were at a considerable
disadvantage. Not only was risk rating permitted, but HIV-
seropositive individuals could be excluded from
membership. As a result, fraudulent claims were common,
and few individuals had access to effective antiretroviral
therapy (ART). The problem was compounded by the high
cost of the drugs, minimal benefits and, at the time, lack of
experience in using ART on the part of many primary health
care doctors.
EARLY DAYS
The aims and objectives of AfA were published shortly after
it was launched in 1998.' In essence, AfA was to be a
comprehensive and confidential disease management
programme with a strong telephonic patient education and
support component and managed access to ART and
related drugs, prophylaxis and monitoring tests. Clinical
support of providers was through well-trained clinical staff
and a 'hands-on' Clinical Advisory Committee drawn from
both the academic and the private sectors. Emphasis was
placed on regular monitoring of CD4 counts and viral loads
and collection of both clinical and claims data.
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Fig. 3. Aid for AIDS enraiment by region {% total lives
covered}.
forward out of fear of disclosing status to the main
member.
Enrolment by region shows that the rate of uptake is
highest in KwaZulu{Natal (1.55%), and lowest in the
Western Cape (0.15%), with more than a tenfold difference
between these regions (Fig. 3). The rate of enrolment per
region will be infiuenced by the underlying HIV prevalence
in the medical scheme membership in that region, as well
as localised factors, such as the level of stigmatisation,
which determine the probability of disclosure.
Fig. 2. Aid for AIDS enralment by age {% total lives covered}.
Cost/month
AfA currently has polymerase chain reaction [PCR) results
for 962 infants where complete mother-to-child
transmission [MTen prophylaxis was provided, mostly
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Fig. 7. Cumulative enralment ofpatients onto the Aid far AIDS
pragramme.
Well over 20 000 people have been registered on AfA to
date, and some 12000 are on ongoing ART [mostly HAARn.
Cover is provided to over 2 million beneficiaries. The staff
complement has grown from 6 to 36 people, and now
includes a dedicated management team, 2 full-time
doctors and 12 nurses and pharmacists, as well as IT and
administrative staff.
,,""',------------------,
Some interesting trends have emerged from the enrolment
data. Most striking is the patient gender distribution, with
61% females and 39% males. This is higher than expected
from AIDS demographic modelling [the prevalence for the
country as a whole is estimated to be marginally higher in
adult women than men),' and may be due in part to
increased awareness of HIV status in pregnant women
through voluntary counselling and testing [VCT). To date,
some 20% of female patients have been pregnant at
registration. Another factor behind male under-enrolment
may be a greater level of denial in males, as this group
remains under-represented even if pregnancy is taken into
account.
The age distribution of patients shows that enrolment is
greatest between 25 and 45 years, with 74% of patients in
this age group (Fig. 2). In total, 93% of patients are older
than 19. There is a surprisingly large difference between
enrolment in 15 - 19-year-olds and in 20 - 24-year-olds
[0.14% v. 0.70010), as well as between the latter and 25 - 29-
year-olds [0.70% v. 207%). This may be because the
majority of the younger patients are dependants - 100%
and 85<\'0 in 15 - 19- and 20 - 24-year-olds respectively,
compared with 30% in 25 - 29-year-olds. There may
therefore be a reluctance in these age groups to come
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350 - 499 15
200 - 349 26
50 - 199 29
< 50 15
THE FUTURE
TABLE Ill. CD4 COUNT DISTRIBUTION AT ENROLMENT ON
THE AID FOR AIDS PROGRAMME
Fig. 5. Hospital admissions relative to commencement ofARI
Months relative to ART commencement
HOSPITALISATION
The aim of any disease management programme (DMP) is
evidence-based case management with continual
evaluation of clinical and economic outcomes, in order to
optimise the use of increasingly scarce health care
resources, limit disease progression and improve overall
health.
Our outcomes show that access to ART reduces the need
for hospitalisation and provides significant reduction in












The hospitalisation data illustrate that admission is
frequently the event which precipitates AfA registration
(Fig. 5). Were all patients to commence ART at the optimal
time, we would not expect to see a peak in admissions
around the enrolment period. The programme has been
monitoring admission rates after commencement of ART
for over 4 years. It has been heartening to see that once
patients have commenced therapy, the admission rate has
stabilised. This is particularly notable considering that the
majority of patients enrolled at a relatively late stage of the
disease. Effectively this has translated into a stable post-
registration cost scenario rather than a steady upward
trend in subsequent years.
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pregnant female patients have enrolled with a CD4 count
< 200 cells/~l, in comparison with 50% of males.
Preliminary results point to entry CD4 count as being a
strong determinant of survival. In particular, patients with
a CD4 count < 50 cells/~1 appear to have a substantially












Fig. 4. Viro/ogicol response to ontiretroviral therapy in Aid for
AIDS patien 15.
The virological response of AfA patients to antiretroviral
therapy is shown in Fig. 4. Most patients started on dual
therapy then switched to HAART. The mean baseline viral
load of patients at commencement of antiretroviral
therapy was 5.01 log 10' It is interesting to note the
improved response to therapy from 27 months onwards.
This is attributed to a greater proportion of patients with
data at these time points having had therapy intensified to
HAART. The virological response at one year (1 10glO
reduction) is associated with a 90% reduction in disease
progression in patients on dual therapy.'
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The CD4 count at registration provides a useful measure of
whether patients have enrolled late [Table Ill). Ideally,
patients should register well before their CD4 count
reaches 200 cells/~1 so that ART can be commenced at the
optimal time. It is of concern that a large percentage of
patients enter the programme with a CD4 count < 200
cells/~1. This is either because patients are ignorant of their
HIV status until they are admitted to hospital for an
opportunistic infection, or because they are in denial. It is
interesting that on average, women (excluding those who
are pregnant at registration) tend to enrol at an earlier CD4










short-course zidovudine for the mother, 6 weeks of
zidovudine for the child, and milk substitutes for 6 months
(Table 11). Most babies were delivered by caesarean section.
The transmission rate of 5.3% is similar to the rate reported
in an earlier study.' Over the past year the use of short-
course HAART has been recommended, and the reduction
in MTCT is expected to improve further.
therapy. We aim to assess the impact of cost reductions in
increasing access to HAART on survival and hope to present
these data in due course. The programme also offers a
valuable education and awareness opportunity for
beneficiaries and employees of contracted medical
schemes and companies, as well as clinical support for
those doctors who require it.
We have identified a number of challenges. These include
communicating more effectively with patients, maintaining
adherence to therapy, and, in common with other HIV
DMP,' addressing the relatively low level of enrolment of
earlier stage patients. We would like to reverse the current
situation where some patients only join the programme
after they are hospitalised for an AIDS-related condition.
It is crucial for all health care workers, including doctors, to
encourage as many people as possible to know their status
and if positive, to join their scheme or company's HIV DMP
long before they are likely to develop an opportunistic
condition.
Continuing to provide optimal therapy within the available
benefit remains an on-going problem as medical schemes
come under increasing pressure from spiralling health care
inflation. This will become even more critical as patients
move on to more complex salvage regimens after a number
of years and the need for sophisticated investigations such
as resistance testing increases.
After more than 4 years AfA has demonstrated that it is
possible to manage HIV costs effectively, and despite the
challenges we have identified, there is no reason why HIV
disease management cannot be extended to far larger
numbers of people.
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